MIRA Pharmaceuticals, Inc.
MIRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $2 | $2 | $1 |
| G&A Expenses | $5 | $6 | $3 | $1 |
| SG&A Expenses | $5 | $6 | $3 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2 | $1 |
| Operating Expenses | $8 | $9 | $7 | $2 |
| Operating Income | -$8 | -$9 | -$7 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$3 | -$0 | -$0 |
| Pre-Tax Income | -$8 | -$12 | -$7 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$12 | -$7 | -$2 |
| % Margin | – | – | – | – |
| EPS | -0.51 | -0.65 | -0.48 | -0.15 |
| % Growth | 21.5% | -35.4% | -220% | – |
| EPS Diluted | -0.51 | -0.65 | -0.48 | -0.15 |
| Weighted Avg Shares Out | 15 | 19 | 15 | 15 |
| Weighted Avg Shares Out Dil | 15 | 19 | 15 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $3 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $7 | $2 |
| EBITDA | -$8 | -$9 | $0 | $0 |
| % Margin | – | – | – | – |